Atlantanews Online

Radiodermatitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Matrix Biomed, Lutris Pharma, FirstString Research, Joben Bio-Medical and Others.

 Breaking News
  • No posts were found

Radiodermatitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Matrix Biomed, Lutris Pharma, FirstString Research, Joben Bio-Medical and Others.

April 21
21:38 2021
Radiodermatitis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Matrix Biomed, Lutris Pharma, FirstString Research, Joben Bio-Medical and Others.

Radiodermatitis Pipeline

Radiation dermatitis is a side effect of external beam ionizing radiation. It is also known as radiodermatitis, x-ray dermatitis, radiation skin damage or a radiation burn. Most commonly, radiation-induced dermatitis is caused by radiotherapy for underlying malignancies. It may also occur due to the exposure to radiation during interventional procedures such as coronary angiography, embolization procedures, and indwelling catheter placements. Irradiation of the skin leads to a complex pattern of direct tissue injury involving damage to cells of the epidermis and endothelial cells within the walls of blood vessels, and inflammatory cell recruitment. Many small studies have investigated the use of topical therapies, as either preventative agents or for management of skin reactions as they occur.

DelveInsight’s, Radiodermatitis Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Radiodermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Some of Radiodermatitis Companies are:

  • Matrix Biomed
  • Lutris Pharma
  • FirstString Research
  • Joben Bio-Medical
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/radiodermatitis-pipeline-insight

 

DelveInsight’s Radiodermatitis Report covers around 3+ products under different phases of clinical development like:

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase II/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Radiodermatitis Therapies are:

  • TEMPOL
  • LUT 014
  • Granexin
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/radiodermatitis-pipeline-insight

 

Current Radiodermatitis Treatment Scenario and Radiodermatitis Emerging Therapies:

  • How many companies are developing Radiodermatitis drugs?
  • How many Radiodermatitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Radiodermatitis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Radiodermatitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Radiodermatitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/radiodermatitis-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Radiodermatitis: Overview

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

Radiodermatitis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Radiodermatitis Collaboration Deals

Late Stage Products (Phase III)

Drug name: Company name

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

TEMPOL: Matrix Biomed

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

Drug name: Company name

Drug profiles in the detailed report…..

Inactive Products

Radiodermatitis Key Companies

Radiodermatitis Key Products

Radiodermatitis- Unmet Needs

Radiodermatitis- Market Drivers and Barriers

Radiodermatitis- Future Perspectives and Conclusion

Radiodermatitis Analyst Views

Radiodermatitis Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/radiodermatitis-pipeline-insight

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/radiodermatitis-pipeline-insight

Related Articles

Categories